Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 19/20 | 0.48 |
| ▸ | PDGFRA | P16234 | 10/20 | 0.48 |
| ▸ | KIT | P10721 | 6/20 | 0.48 |
| ▸ | PDGFRB | P09619 | 7/20 | 0.47 |
| ▸ | FLT3 | P36888 | 3/20 | 0.47 |
| ▸ | KDR | P35968 | 2/20 | 0.47 |
| ▸ | MET | P08581 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23900575 | 0.83 | CSF1R (0.49) | CSF1RPDGFRAKITPDGFRBFLT3 | |
| SCHEMBL16561327 | 0.80 | CCR1 (0.58) | CSF1RPDGFRAKITPDGFRBFLT3 | |
| SCHEMBL16029060 | 0.78 | CSF1R (0.51) | CSF1RPDGFRAKITPDGFRBFLT3 | |
| SCHEMBL14447156 | 0.78 | FYN (0.58) | CSF1RPDGFRAKITPDGFRBFLT3 | |
| SCHEMBL23071266 | 0.77 | CSF1R (0.50) | CSF1RPDGFRAKITPDGFRBFLT3 | |
| SCHEMBL29736609 | 0.77 | CSF1R (0.50) | CSF1RPDGFRAKITPDGFRBFLT3 | |
| SCHEMBL23900573 | 0.77 | CSF1R (0.48) | CSF1RPDGFRAKITPDGFRBFLT3 | |
| SCHEMBL24316443 | 0.77 | CSF1R (0.59) | CSF1RPDGFRAKITPDGFRBFLT3 | |
| SCHEMBL16060927 | 0.76 | CSF1R (0.56) | CSF1RPDGFRAKITPDGFRBFLT3 | |
| SCHEMBL2416158 | 0.76 | CSF1R (0.54) | CSF1RPDGFRAKITPDGFRBFLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022057895-A1 | HETEROAROMATIC COMPOUNDS AND USES THEREOF | HUTCHISON MEDIPHARMA LIMITED (CN) | 2022-03-24 | — | — | WO | disclosed |